Molecular dynamic simulations and structure-based pharmacophore development for farnesyltransferase inhibitors discovery

References

• International Agency for Research on Cancer, WHI; 2014. Available from: http://www.iarc.fr/en/publications/books/wcr/wcr-order.php
   Google Scholar
• World Health Organization; 2015. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/
   Google Scholar
• Moorthy NSHN, Sousa SF, Ramos MJ, Fernandes PA. Structural feature study of benzofuran derivatives as farnesyltransferase inhibitors. J Enzyme Inhib Med Chem 2011;26:777–91
   PubMed Web of Science ®Google Scholar
• Witzig TE, Tang H, Micallef INM, et al. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood 2011;118:4882–9
   PubMed Web of Science ®Google Scholar
• Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241–69
   PubMed Web of Science ®Google Scholar
• Moorthy NSHN, Sousa SF, Ramos MJ, Fernandes PA. Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis. Curr Med Chem 2013;20:4888–923
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Trobridge P, Buckner FS, et al. Protein farnesyltransferase from Trypanosoma brucei. A heterodimer of 61- and 65-kda subunits as a new target for antiparasite therapeutics. J Biol Chem 1998;273:26497–505
   PubMed Web of Science ®Google Scholar
• Capell BC, Erdos MR, Madigan JP, et al. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson–Gilford progeria syndrome. Proc Natl Aacd Sci USA 2005;102:12879–84
   PubMed Web of Science ®Google Scholar
• Ohkanda J, Buckner FS, Lockman JW, et al. Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. J Med Chem 2004;47:432–45
   PubMed Web of Science ®Google Scholar
• Buckner FS, Eastman RT, Nepomuceno-Silva JL, et al. Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major. Mol Biochem Parasitol 2002;122:181–8
   PubMed Web of Science ®Google Scholar
• Esteva MI, Kettler K, Maidana C, et al. Benzophenone-based farnesyltransferase inhibitors with high activity against Trypanosoma cruzi. J Med Chem 2005;48:7186–91
   PubMed Web of Science ®Google Scholar
• Troutman JM, Subramanian T, Andres DA, Spielmann HP. Selective modification of CaaX peptides with ortho-substituted anilinogeranyl lipids by protein farnesyltransferase: competitive substrates and potent inhibitors from a library of farnesyl diphosphate analogues. Biochemistry 2007;46:11310–21
   PubMed Web of Science ®Google Scholar
• Eastman RT, White J, Hucke O, et al. Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J Biol Chem 2005;280:13554–9
   PubMed Web of Science ®Google Scholar
• Buckner FS, Eastman RT, Yokoyama K, et al. Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. Curr Opin Investig Drugs 2005;6:791–7
   PubMedGoogle Scholar
• Straniero V, Pallavicini M, Chiodini G, et al. Farnesyltransferase inhibitors: CAAX mimetics based on different biaryl scaffolds. Bioorg Med Chem Lett 2014;24:2924–7
   PubMed Web of Science ®Google Scholar
• Reid TS, Long SB, Beese LS. Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes. Biochemistry 2004;43:9000–8
   PubMed Web of Science ®Google Scholar
• Shen M, Pan P, Li Y, et al. Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling. Drug Discov Today 2015;20:267–76
   PubMed Web of Science ®Google Scholar
• Moorthy NSHN, Sousa SF, Ramos MJ, Fernandes PA. In silico based structural analysis of arylthiophene derivatives for FTase inhibitory activity, hERG and other toxic effects. J Biomol Screen 2011;16:1037–46
   PubMed Web of Science ®Google Scholar
• Loving K, Salam NK, Sherman W. Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. J Comput Aided Mol Des 2009;23:541–54
   PubMed Web of Science ®Google Scholar
• Sanders MPA, Verhoeven S, de Graaf C, et al. Snooker: a structure-based pharmacophore generation tool applied to class A GPCRs. J Chem Inf Model 2011;51:2277–92
   PubMed Web of Science ®Google Scholar
• Meslamani J, Li J, Sutter J, et al. Protein − ligand-based pharmacophores: generation and utility assessment in computational ligand profiling. J Chem Inf Model 2012;52:943–55
   PubMed Web of Science ®Google Scholar
• Rella M, Rushworth CA, Guy JL, et al. Structure-based pharmacophore design and virtual screening for novel angiotensin converting enzyme 2 inhibitors. J Chem Inf Model 2006;46:708–16
   PubMed Web of Science ®Google Scholar
• Chen J, Lai L. Pocket v.2: further developments on receptor-based pharmacophore modeling. J Chem Inf Model 2006;46:2684–91
   PubMed Web of Science ®Google Scholar
• Kurczab R, Bojarski AJ. New strategy for receptor-based pharmacophore query construction: a case study for 5-HT7 receptor ligands receptor. J Chem Inf Model 2013;53:3233–43
   PubMed Web of Science ®Google Scholar
• Arooj M, Sakkiah S, Kim S, et al. A combination of receptor-based pharmacophore modeling & QM techniques for identification of human chymase inhibitors. PLoS One 2013;8:e63030
   PubMed Web of Science ®Google Scholar
• Guner OF. History and evolution of the pharmacophore concept in computer-aided drug design. Curr Top Med Chem 2002;2:1321–32
   PubMedGoogle Scholar
• Dixon SL, Smondyrev AM, Knoll EH, et al. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 2006;20:647–71
   PubMed Web of Science ®Google Scholar
• Guner O, Clement O, Kurogi Y. Pharmacophore modeling and three dimensional database searching for drug design using catalyst: recent advances. Curr Med Chem 2004;11:2991–3005
   PubMed Web of Science ®Google Scholar
• Protein Data Bank; 2014. Available from: http://www.rcsb.org/pdb/home/home.do
   Google Scholar
• Case DA, Darden TA, Cheatham IIITE, et al. AMBER 12. San Francisco: University of California; 2012
   Google Scholar
• Sousa SF, Fernandes PA, Ramos MJ. Farnesyltransferase-new insights into the zinc-coordination sphere paradigm: evidence for a carboxylate-shift mechanism. Biophys J 2005;88:483–94
   PubMed Web of Science ®Google Scholar
• Long SB, Casey PJ, Beese LS. Reaction path of protein farnesyltransferase at atomic resolution. Nature 2002;419:645–50
   PubMed Web of Science ®Google Scholar
• Long SB, Hancock PJ, Kral AM, et al. The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics. Proc Natl Acad Sci USA 2001;98:12948–53
   PubMed Web of Science ®Google Scholar
• Park HW, Boduluri SR, Moomaw JF, et al. Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. Science 1997;275:1800–4
   PubMed Web of Science ®Google Scholar
• Tobin DA, Pickett JS, Hartman HL, et al. Structural characterization of the zinc site in protein farnesyltransferase. J Am Chem Soc 2003;125:9962–9
   PubMed Web of Science ®Google Scholar
• Pickett JS, Bowers KE, Fierke CA. Mutagenesis studies of protein farnesyltransferase implicate aspartate beta 352 as a magnesium ligand. J Biol Chem 2003;278:51243–50
   PubMed Web of Science ®Google Scholar
• Pickett JS, Bowers KE, Hartman HL, et al. Kinetic studies of protein farnesyltransferase mutants establish active substrate conformation. Biochemistry 2003;42:9741–8
   PubMed Web of Science ®Google Scholar
• Sousa SF, Fernandes PA, Ramos MJ. Effective tailor-made force field parameterization of the several Zn coordination environments in the puzzling FTase enzyme: opening the door to the full understanding of its elusive catalytic mechanism. Theor Chem Acc 2007;117:171–81
   Web of Science ®Google Scholar
• Sousa SF, Fernandes PA, Ramos MJ. Theoretical studies on farnesyltransferase: the distances paradox explained. Proteins 2007;66:205–18
   PubMed Web of Science ®Google Scholar
• Sousa SF, Fernandes PA, Ramos MJ. Molecular dynamics simulations on the critical states of the farnesyltransferase enzyme. Bioorg Med Chem 2009;17:3369–78
   PubMed Web of Science ®Google Scholar
• Duan Y, Wu C, Chowdhury S, et al. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 2003;24:1999–2012
   PubMed Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics – molecular. J Mol Graph 1996;14:33–38
   PubMed Web of Science ®Google Scholar
• Molecular operating environment (MOE). Chemical Computing Group Inc. Montreal, H3A 2R7 Canada; 2013
   Google Scholar
• Vasanthanathan P, Moorthy NSHN, Kongsted J. Dual mechanism of HIV-1 integrase and RNase H inhibition by diketo derivatives: a computational study. RSC Adv 2014;4:38672–81
   Web of Science ®Google Scholar
• Moorthy NSHN, Cerquira NMFS, Ramos MJ, Fernandes PA. Ligand based analysis on HMG-CoA reductase inhibitors. Chemom Intell Lab Sys 2015;140:102–16
   Web of Science ®Google Scholar
• Sousa SF, Fernandes PA, Ramos MJ. Enzyme flexibility and the catalytic mechanism of farnesyltransferase: targeting the relation. J Phys Chem B 2008;112:8681–91
   PubMed Web of Science ®Google Scholar
• Sousa SF, Fernandes PA, Ramos MJ. Theoretical studies on farnesyl transferase: evidence for thioether product coordination to the active-site zinc sphere. J Comput Chem 2007;28:1160–8
   PubMed Web of Science ®Google Scholar
• Sousa SF, Coimbra JTS, Paramos D, et al. Molecular dynamics analysis of a series of 22 potential farnesyltransferase substrates containing a CaaX-motif. J Mol Model 2013;19:673–88
   PubMed Web of Science ®Google Scholar